Verve Therapeutics, Inc.
Pioneer new approaches to the treatment of cardiovascular disease (CVD) and develop new therapies through in vivo gene editing. Focusing on the PCSK9 and ANGPTL3 genes, mimicking natural disease-resistant mutations and turning off specific genes to lower blood lipids and reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Delaware-born
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 255 |
Founded | 2018 |
Financials | |
|---|---|
Market Capitalization | 565.09M |
Revenue | 16.05M |
Operating Income | -221.71M |
Operating Margin | -1381.45% |
Net Income | -196.83M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 5110 / 5373 |
Sector : Healthcare | 1044 / 1144 |
Industry : Biotechnology | 573 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2890 / 5565 |
Sector : Healthcare | 416 / 1182 |
Industry : Biotechnology | 191 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 5080 / 5436 |
Sector : Healthcare | 1045 / 1164 |
Industry : Biotechnology | 578 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3403 / 5330 |
Sector : Healthcare | 416 / 1174 |
Industry : Biotechnology | 112 / 667 |